Evaluation of Phase I Demonstrations of the Pharmacy Quality Alliance
Pharmacist Survey
Form
Approved
OMB No. 0935-XXXX
Exp. Date XX/XX/20XX
EVALUATION OF PHASE I DEMONSTRATIONS OF THE PHARMACY QUALITY ALLIANCE
PHARMACIST SURVEY
Thank you for participating in this electronic survey. The primary purpose of the survey is to gain a better understanding of pharmacists’ perspectives on the demonstration project. In addition, we seek to understand pharmacists’ general beliefs about pharmacy quality improvement.
This is an independent evaluation funded by the Agency for Healthcare Research and Quality (AHRQ). Individual responses will be kept confidential;private Your responses will be kept confidential to the extent permitted by law, including AHRQ’s confidentiality statute, 42 USC 299c-3(c); results will only be shared in aggregate at the site level.
T
Public
reporting burden for this collection of information is estimated to
average 30
minutes per response, the estimated time required to complete
the survey. An agency may not conduct or sponsor, and a person
is not required to respond to, a collection of information unless it
displays a currently valid OMB control number. Send
comments regarding this burden estimate or any other aspect of
this collection of information, including suggestions for reducing
this burden, to: AHRQ Reports Clearance Officer Attention: PRA,
Paperwork Reduction Project (0935-XXXX) AHRQ,
540 Gaither Road, Room # 5036, Rockville, MD 20850.
Return of the completed survey will serve as your implied consent to participate.
The next series of questions pertain to whether you believe each of the 15 PQA Performance measures is important to improving patient care, and whether you believe that you can improve your pharmacy’s performance on each measure.
PQA Measure |
Is this measure important to improving patient care?
|
Do you believe that this measure provides you with enough information to intervene with physicians regarding your patients’ care? |
1. Proportion of Days Covered: Beta Blockers |
Yes No I don’t know |
Yes No I don’t know |
2. Proportion of Days Covered: ACE Inhibitors/ARBs |
Yes No I don’t know |
Yes No I don’t know |
3. Proportion of Days Covered: Calcium Channel Blockers |
Yes No I don’t know |
Yes No I don’t know |
4. Proportion of Days Covered: Dyslipidemia Medications |
Yes No I don’t know |
Yes No I don’t know |
5. Proportion of Days Covered: Diabetes Medications |
Yes No I don’t know |
Yes No I don’t know |
6. Gap in Therapy: Beta Blockers |
Yes No I don’t know
|
Yes No I don’t know |
7. Gap in Therapy: ACE Inhibitors/ARBs |
Yes No I don’t know |
Yes No I don’t know |
8. Gap in Therapy: Calcium Channel Blockers |
Yes No I don’t know |
Yes No I don’t know |
9. Gap in Therapy: Dyslipidemia Medications |
Yes No I don’t know |
Yes No I don’t know |
10. Gap in Therapy: Diabetes Medications |
Yes No I don’t know |
Yes No I don’t know |
11. Diabetes: Excessive Doses of Oral Medications |
Yes No I don’t know |
Yes No I don’t know |
12. Diabetes: Suboptimal Treatment of Hypertension |
Yes No I don’t know |
Yes No I don’t know |
13. Asthma: Suboptimal Control |
Yes No I don’t know
|
Yes No I don’t know |
14. Asthma: Absence of Controller Therapy |
Yes No I don’t know |
Yes No I don’t know |
15. High-Risk Medications in the Elderly |
Yes No I don’t know |
Yes No I don’t know |
16. Summary values (6 aggregate measures) |
Yes No I don’t know |
Yes No I don’t know |
PQA Phase I Demonstration project leaders sought your input in the design of the performance reports |
1 Strongly Disagree |
2
|
3
Neutral |
4
|
5
Strongly Agree |
Not applicable |
The reports were informative about your pharmacy’s performance |
1 Strongly Disagree |
2
|
3
Neutral |
4
|
5
Strongly Agree |
Not applicable |
The reports were useful to identify areas to target for improvement |
1 Strongly Disagree |
2
|
3
Neutral |
4
|
5
Strongly Agree |
Not applicable |
The content of the reports was easy to understand |
1 Strongly Disagree |
2
|
3
Neutral |
4
|
5
Strongly Agree |
Not applicable |
The format of the reports was easy to read (considering the font size, layout, color scheme) |
1 Strongly Disagree |
2
|
3
Neutral |
4
|
5
Strongly Agree |
Not applicable |
The reports allowed you to see how you were doing compared to other pharmacies |
1 Strongly Disagree |
2
|
3
Neutral |
4
|
5
Strongly Agree |
Not applicable |
The reports were easy to access |
1 Strongly Disagree |
2
|
3
Neutral |
4
|
5
Strongly Agree |
Not applicable |
Limited training about how to use the pharmacy performance reports
|
1 Not a barrier at all |
2
|
3
Somewhat of a barrier |
4
|
5
Significant barrier |
I don’t know |
Does not apply |
Limited training about the field of quality measurement and improvement |
1 Not a barrier at all |
2
|
3
Somewhat of a barrier |
4
|
5
Significant barrier |
I don’t know |
Does not apply |
Lack of organizational support |
1 Not a barrier at all |
2
|
3
Somewhat of a barrier |
4
|
5
Significant barrier |
I don’t know |
Does not apply |
Lack of time |
1 Not a barrier at all |
2
|
3
Somewhat of a barrier |
4
|
5
Significant barrier |
I don’t know |
Does not apply |
Pharmacy technicians not engaged in quality improvement activities |
1 Not a barrier at all |
2
|
3
Somewhat of a barrier |
4
|
5
Significant barrier |
I don’t know |
Does not apply |
Not compensated for quality improvement activities |
1 Not a barrier at all |
2
|
3
Somewhat of a barrier |
4
|
5
Significant barrier |
I don’t know |
Does not apply |
Fear of making a medication error if quality improvement tasks interrupt workflow |
1 Not a barrier at all |
2
|
3
Somewhat of a barrier |
4
|
5
Significant barrier |
I don’t know |
Does not apply |
Frequent job interruptions make it difficult to focus on quality improvement tasks |
1 Not a barrier at all |
2
|
3
Somewhat of a barrier |
4
|
5
Significant barrier |
I don’t know |
Does not apply |
Pharmacists do not have sufficient legal authority to change prescriptions |
1 Not a barrier at all |
2
|
3
Somewhat of a barrier |
4
|
5
Significant barrier |
I don’t know |
Does not apply |
Physicians are not engaged in pharmacy quality programs |
1 Not a barrier at all |
2
|
3
Somewhat of a barrier |
4
|
5
Significant barrier |
I don’t know |
Does not apply |
Product shortages could impact performance results by leading to perceived gaps in therapy |
1 Not a barrier at all |
2
|
3
Somewhat of a barrier |
4
|
5
Significant barrier |
I don’t know |
Does not apply |
Pharmacists should play a role in improving the quality of medication prescribing
|
1 Strongly Disagree |
2
|
3
Neutral |
4
|
5
Strongly Agree |
I don’t know |
Pharmacists need to broaden their responsibilities by taking on roles in quality and performance improvement projects |
1 Strongly Disagree |
2
|
3
Neutral |
4
|
5
Strongly Agree |
I don’t know |
Pharmacists should take on leadership roles in quality improvement activities |
1 Strongly Disagree |
2
|
3
Neutral |
4
|
5
Strongly Agree |
I don’t know |
Participation in this project resulted in an increased interest in quality improvement in my organization |
1 Strongly Disagree |
2
|
3
Neutral |
4
|
5
Strongly Agree |
I don’t know |
Pharmacists need a financial incentive in order to engage in quality improvement |
1 Strongly Disagree |
2
|
3
Neutral |
4
|
5
Strongly Agree |
I don’t know |
Pharmacists should be rewarded for achieving success with the pharmacy quality measures |
1 Strongly Disagree |
2
|
3
Neutral |
4
|
5
Strongly Agree |
I don’t know |
Pharmacists must be required (e.g. by law, regulation or accreditation) to participate in quality improvement initiatives |
1 Strongly Disagree |
2
|
3
Neutral |
4
|
5
Strongly Agree |
I don’t know |
In general, I feel empowered to improve pharmacy quality |
1 Strongly Disagree |
2
|
3
Neutral |
4
|
5
Strongly Agree |
I don’t know |
Your overall perception of the PQA Phase 1 Demonstration project: |
1 Un-favorable |
2
|
3
Neutral |
4
|
5
Favorable |
I don’t know |
CNA
/ Jefferson Medical College
| File Type | application/msword |
| File Title | Evaluation of Phase I Demonstrations of the Pharmacy Quality Alliance |
| Author | Danie C. Pizzi |
| Last Modified By | wcarroll |
| File Modified | 2009-10-21 |
| File Created | 2009-10-21 |